GlassScriptPhysician profile
Norman Fishman
NPI 1528086659
$4,315.86
in general payments reported to CMS, 2019-2025
50 companies · $666 in 2025
The $666 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $478 · 2021: $1,197 · 2022: $362 · 2023: $576 · 2024: $466 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Senseonics, Incorporated | $421.00 | 2019-2021 | |
| Novo Nordisk INC | $324.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $301.41 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $240.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $216.95 | 2019-2023 | Farxiga |
| Medtronic, INC. | $209.01 | 2021-2025 | Minimed 780g, Inceptiv, Intellis Adaptivestim |
| Dexcom, INC. | $193.83 | 2019-2021 | |
| Lilly USA, LLC | $171.49 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Medtronic Minimed, INC. | $162.08 | 2019-2020 | |
| Horizon Therapeutics Plc | $157.43 | 2020-2021 | |
| Corcept Therapeutics | $152.44 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.41 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $106.31 | 2019-2024 | |
| Amgen INC. | $103.16 | 2019-2025 | Tepezza, Repatha, Evenity |
| Amarin Pharma, INC. | $101.05 | 2019-2021 |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.